Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.

[1]  E. H. Lambert,et al.  The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy , 2007, BJU international.

[2]  H. Woo,et al.  Management of stage T1 tumors of the bladder: International Consensus Panel. , 2005, Urology.

[3]  Å. Månsson,et al.  Quality of life in patients with bladder cancer. , 2005, Urologic oncology.

[4]  V. Ficarra,et al.  Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma , 2005, BJU international.

[5]  M. O'Donnell,et al.  Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. , 2004, The Journal of urology.

[6]  D. Grignon,et al.  Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. , 2004, Urologic oncology.

[7]  G. Dalbagni,et al.  Defining bacillus Calmette-Guerin refractory superficial bladder tumors. , 2003, The Journal of urology.

[8]  D. Lamm,et al.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. , 2002, The Journal of urology.

[9]  M. O'Donnell,et al.  Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. , 2001, The Journal of urology.

[10]  Michael Cookson,et al.  Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. , 2001, The Journal of urology.

[11]  G. Bartsch,et al.  Life after cystectomy and orthotopic neobladder versus ileal conduit urinary diversion. , 2001, Seminars in urologic oncology.

[12]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Lamm,et al.  Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. , 2000, The Journal of urology.

[14]  R. Bahnson,et al.  EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER , 2000 .

[15]  D. Johnston,et al.  A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. , 2000, The Journal of urology.

[16]  D. Lamm,et al.  MAINTENANCE BCG IMMUNOTHERAPY: EVIDENCE OF ADDITIONAL PROTECTION AGAINST CANCER , 1999 .

[17]  H. Grossman,et al.  Relationship among cystectomy, microvessel density and prognosis in stage T1 transitional cell carcinoma of the bladder. , 1998, The Journal of urology.